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There has been a rapid expansion in our understanding of the diversity and complexity of the 
genital tract microbiome over the past decade and our ability to detect these micro-organisms 
(microbiota) using sensitive and specific nucleic acid amplification tests (NAATs).1-5  There is 
increasing evidence that transmission of these microbiota is the norm after unprotected sexual 
intercourse, with no risk of disease associated with the majority of microbiota transferred.1, 2, 4   
We would like to propose the term sexually shared microbiota (SSM) in order to avoid them 
being described as causing sexually transmitted infections (STIs) which is potentially 
stigmatizing and likely to promote the need for treatment.3 
  This article adds further to the debate 6-11  on the meaning and use of the terms “sexually 
transmitted infection” (STI) and “sexually transmitted disease” (STD) and considers whether 
they remain fit for purpose when applied to all genital- tract microbiota. Traditional STIs 12 
(bacterial, viral, protozoal, and fungal) are transmitted from an individual to a recipient host 
mainly during sexual activity, to become attached to or to penetrate cells of the genital or other 




site(s) of the host and multiply, causing an infection. This event, usually in association with a 
subsequent immunological reaction, may cause damage, sometimes of sufficient severity to 
bring about dis-ease with associated symptoms and signs. The larger the number of organisms 
involved (or the greater the “bacterial or viral load”) the greater the chance of damage occurring 
and thus a risk of the host developing clinical symptoms and/or signs, with host factors also 
being important.13-15 However, strictly speaking, neither infection nor disease are transmitted; 
it is merely the organisms that are transmitted. It follows that the terms or their abbreviations, 
STI and STD, are technically misnomers. However, they may be seen as short-hand for “sexual 
transfer of a micro-organism causing infection of, or disease of--” and have been used for 
decades, STI gradually creeping in after STD in recognition that many infections may remain 
asymptomatic,7 although not necessarily without damage. So, avoiding these terms would seem 
obtuse, despite their apparent irrational meaning. It has been suggested that STI and STD may 
be used synonymously,7,8 but we think differently. Although STI usage followed that of STD, 
the fact is that mechanistically disease follows, or may follow, infection. This caveat is 
emphasized by damage also being influenced by the nature of the micro-organism. Thus, for 
example, Neisseria gonorrhoeae or Chlamydia trachomatis are intrinsically much more likely 
to produce disease (some say traditional or “real” STDs) than are Ureaplasma spp. or 
M.hominis.16,17  In addition, these terms are not used to describe genital human papilloma 
viruses (HPV) which cause cervical cancer in only a minority of those infected, presumably 
because of the stigma associated with these terms and that there is no effective treatment.10, 11 
Public Health England in their patient cervical screening leaflet state “HPV can be easily 
passed on during sexual activity between partners”18, and WHO uses the term “sexually 
acquired infection”.19 Transmission of lactobacilli is unlikely to cause harm. Thus, there is 
clearly a spectrum of health to disease associated with sexual transmission of oral ano-genital 
tract microbiota.  The proposal 11 to use a single term, namely “Sexually Transmissible 




Infectious Disease”, may find favour with a few, but it does suggest, wrongly, that all infections 
result in disease.  
   As indicated above, we will not go out of our way to avoid using STI or STD when a 
distinction between infection and disease is to be made, nor suggest that well-known journals 
do so in their titles. We know that many physicians dealing with patients refer to STIs rather 
than STDs, the former being marginally less emotive.9,10 This is a practice that should continue. 
However, when should a genital tract micro-organism detected by NAAT be referred to as 
causing an STI/STD with the implication that treatment is required and when should it be 
considered part of the normal genital-tract microbiota? The mere presence of Mycoplasma 
hominis, Ureaplasma urealyticum and Ureaplasma parvum in the genital tract does not 
categorize them as pathogens. In this regard, a recent review of the literature concluded that 
asymptomatic carriage of these mycoplasmas is common and routine testing and treatment of 
asymptomatic or symptomatic men and women is not recommended as there is no evidence 
that more good than harm is being done.17 Indeed, not only does it increase the risk of 
antimicrobial resistance17, it is also known that antibiotic therapy may dramatically change the 
gut and oral microbiomes 20 and the genital-tract microbiome can’t be different. It is disturbing, 
therefore, that an increasing number of commercial websites are offering NAAT testing for 
these mycoplasmas, describing them as STIs, with treatment if detected. We discuss this in 
more detail in our review article.3 The idea of SSM is not new but it emphasizes that 
transmission of microbiota is a normal part of unprotected sexual intercourse. This terminology 
might be taken up more rapidly by the scientific community than by physicians and the public, 
although we should not underestimate their intelligence and understanding. We see SSM as a 
valuable additional aid in scientific discourse and also as an everyday part of our expert clinical 
guidance for patients and the public. It is noteworthy that the ‘gut microbiome’ has been 




common parlance for years and that the ‘skin microbiome’ is currently a feature of television 
exposure. SSM may well follow. 
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